Hair Loss Was Just the Start. Ozempic Users Are Also Reporting Nail Trouble

GLP-1 receptor agonists such as semaglutide (Ozempic) and tirzepatide are linked with higher rates of hair and nail problems in two cross-sectional studies by a European team (SCOP-GLP1) that surveyed people treated for type 2 diabetes or obesity. Each analysis compared 575 GLP-1 users with 1,379 matched non-users across France, the U.S., Brazil and Mexico; average treatment duration was 18.5 months. About half of GLP-1 users reported unusual hair loss versus roughly a third of controls, and scalp irritation was more common; these hair complaints did not track with the amount of weight lost. Nail complaints were also more frequent: 66% of GLP-1 users versus 53% of controls reported nail problems, with nail detachment reported by ~39% of users versus 9% of controls and nail discoloration by 46% versus 17%.

The analyses are based on self-reported symptoms, have not yet been peer reviewed, and describe associations rather than proving causation; the project was funded by Pierre Fabre, a company with commercial interests in hair products. Investigators plan a prospective clinical study to objectively track skin, hair and nail outcomes over time. Meanwhile clinicians are advised to check for scalp signs (itching, redness, scaling) and interpret nail changes in the context of overall health and nutrition; patients are urged to report symptoms to their doctors rather than stopping effective GLP-1 therapy unilaterally.